If the cells you would like to access are currently listed as unavailable
              or you are ordering from outside of Europe please get in touch via
              Contact@EBiSC.org.
          
    			BIONi010-A
	
	K1P53	
        			        			iPSC line
                                    A CLIP contains information about a cell line including any
                                    specific third party obligations relating to, for example,
                                    licensing obligations or the donor consent which affect the
                                    use of the cell line.
                                
                                                        
                                    The EBiSC Access and Use Agreement must be completed along with an individual
                                    Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org
                                    for countersignature. The EAUA must be fully signed before proceeding with your order.
                                
                                                    
                                A batch specific Certificate of Analysis will be available to
                                download once you receive your EBiSC iPSC line.
                            
                        General#
Cell Line | 
					|
| hPSCreg name | BIONi010-A | 
| Alternative name(s) | 
									 
	K1P53	 
							 | 
						
| Cell line type | Human induced pluripotent stem cell (hiPSC) | 
| Similar lines | 
							 BIONi010-C-13 (BIONi010-C + NGN2 #I7-26) BIONi010-C-3 (BIONi010-C ApoE KO #KO30 P30) BIONi010-C-15 (BIONi010-C +dox inducible NGN2-GFP) BIONi010-C-25 (BIONi010-C heterozygous TREM2 KO) BIONi010-C-17 (BIONi010-C TREM2 KO) BIONi010-B (K2P53, BIONi010-B) BIONi010-C (BIONi010-C, K3P53) BIONi010-C-70 (BIONi010-C with an APOE 2/2 genotype with an additional, homozygous christchurch mutation) BIONi010-C-71 (BIONi010-C with an APOE 3/3 genotype with an additional, homozygous christchurch mutation) BIONi010-C-4 (BIONi010-C ApoE E4/E4 #B44 P27) BIONi010-C-5 (BIONi010-C CD33 E2del #N14 P26) BIONi010-C-2 (BIONi010-C ApoE E3/E3 #H8 P32) BIONi010-C-6 (BIONi010-C ApoE E2/E2) BIONi010-C-7 (BIONi010-C Trem2 R47H) BIONi010-C-8 (BIONi010-C Trem2 T66M, #Y5-80) BIONi010-C-9 (BIONi010-C CD33 KO) BIONi010-C-51 (BIONi010-C TNNI3-mCherry reporter) BIONi010-C-18 (BIONi010-C TBK1 KO) BIONi010-C-19 (BIONi010-C IKBKE KO) BIONi010-C-10 (HNF1AP291fsinsC +/- 54-5) BIONi010-C-11 (HNF1AP291fsinsC -/- 66-1) BIONi010-C-12 (HNF4ApR309C -/- 2-4) BIONi010-C-52 (BIONi010-C with an APOE 2/2 genotype (with two functional alleles in contrast to BIONi010-C-6)) BIONi010-C-53 (BIONi010-C with an APOE 3/3 genotype (with two functional alleles in contrast to BIONi010-C-2)) BIONi010-C-55 (BIONi010-C TNNI3-mCherry/TNNI1-EGFP dual reporter cl. 74) BIONi010-C-24 (BIONi010-C Dox a-syn)  | 
					
Provider | 
					|
| Depositor | Bioneer (BION) | 
| Owner | Bioneer (BSC) | 
| Distributors | 
															 
									Bioneer (BSC)																																	 
															
									EBiSC																																																																																																																																																													 
														 | 
						
| Derivation country | Denmark | 
External Databases | 
						|
| hPSCreg | BIONi010-A | 
| BioSamples | SAMEA3105765 | 
| Cellosaurus | CVCL_1E66 | 
| Wikidata | Q54796746 | 
							    
							General Information | 
					|
| Publications | |
| This EBiSC line can be used for: | 
                                 Yes 
                                Research use: allowed 
                                Clinical use: no 
                                Commercial use: no 
                             | 
                        
Donor Information#
General Donor Information | 
					|
| Sex | male | 
| Age of donor (at collection) | 15-19 | 
| Ethnicity | Black or African-American | 
Phenotype and Disease related information (Donor) | 
					|
| Diseases | No disease was diagnosed.
																	 | 
					
Other Genotyping (Donor) | 
						|
| Is there genome-wide genotyping or functional data available? | 
								 No 								
															 | 
						
Donor Relations | 
							|
| Other cell lines of this donor | |
External Databases (Donor) | 
						|
| BioSamples | SAMEA3105780 | 
hIPSC Derivation#
General | 
						|
| Source cell line name | 
															CC-2511																										 Derived from same source line (potentially other lot and donor, see below):
							
							 
													 | 
						
| Source cell type | 
										
				
	
			 A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative. 
	
									 | 
							
| Source cell origin | 
										
				
	
			 Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis. 
	
			Synonyms 
		
  | 
							
| Source cell type (free text) | NHDF-Ad-Der Fibroblasts | 
| Source cell line lot number | 
									 0000208364 
																	Derived from same source line lot:
									
									 
																 | 
							
| Age of donor (at collection) | 15-19 | 
| Source cell line vendor | LONZA | 
Reprogramming method | 
						|
| Vector type | Non-integrating | 
| Vector | Episomal | 
| Genes | |
Vector free reprogramming | 
						|
Other | 
						|
| Derived under xeno-free conditions | 
								 No 							 | 
						
| Derived under GMP? | 
								 No 							 | 
						
| Available as clinical grade? | 
								 No 							 | 
						
Culture Conditions#
					The following are the depositor culture conditions, they do not refer to any specific batch.
				
			
			| Surface coating | Matrigel/Geltrex | 
| Feeder cells | 
															 No 														 | 
						
| Passage method | 
								Enzymatically
								
																			 
											Dispase										 
																	
								
							 | 
						
| O2 Concentration | 5 % | 
| CO2 Concentration | 5 % | 
| Medium | 
								mTeSR™ 1		
		
								 | 
						
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes  | 
					
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles | 
| NANOG | 
											 Yes 						                 | 
																                
						                
						                	 | 
						                
							                 | 
						                |||
| POU5F1 (OCT-4) | 
											 Yes 						                 | 
																                
						                
						                	 | 
						                
							                 | 
						                |||
| SSEA-3 | 
											 Yes 						                 | 
																                
						                
						                	 | 
						                ||||
| SSEA-4 | 
											 Yes 						                 | 
																                
						                
						                	 | 
						                ||||
| TRA 1-60 | 
											 Yes 						                 | 
																                
						                
						                	 | 
						                ||||
| TRA 1-81 | 
											 Yes 						                 | 
																                
						                
						                	 | 
						                ||||
| DNMT3B | 
											 Yes 						                 | 
																                
						                
							                 | 
						                ||||
| SOX2 | 
											 Yes 						                 | 
																                
						                
							                 | 
						                
Differentiation Potency
In vitro spontaneous differentiation
In vitro directed differentiation
					| Marker | Expressed | 
| Tuj1 | 
										 Yes 					                 | 
								
| NES | 
										 Yes 					                 | 
								
| VIMENTIN | 
										 Yes 					                 | 
								
| vGLUT1 | 
										 Yes 					                 | 
								
Microbiology / Virus Screening | 
						|
| HIV 1 | Negative | 
| HIV 2 | Negative | 
| Hepatitis B | Negative | 
| Hepatitis C | Negative | 
| Mycoplasma | Negative | 
Sterility | 
						|
| Inoculation for microbiological growth | No Contaminants Detected | 
| Mycoplasma | Not Detected | 
| Viability | Viable post-cryopreservation | 
Genotyping#
Karyotyping (Cell Line) | 
					|
| Has the cell line karyotype been analysed? | 
								 Yes 								
																	
															 | 
						
Other Genotyping (Cell Line) | 
					|
| Is there genome-wide genotyping or functional data available? | 
								 Yes 								
																											
											Whole genome sequencing											
											 
																								https://ega-archive.org/studies/EGAS00001002755 This cell line has undergone WGS using the Illumina HiSeq X platform at 30x coverage. Fastq files are stored at the European Genome Archive, users can apply for access to this data by submitting an application form to the EBiSC Data Access Committee https://ega-archive.org/dacs/EGAC00001000768  |